2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1694

All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Abstract Number: 2718

Along Those Lines: Synoviocyte Cell-to-Cell Communication Via Nanotubes
Abstract Number: 2120

Alterations in Complement C3 and iC3b in SLE Pregnancies
Abstract Number: 1758

Alterations in Nuclear Structure Promote Lupus Autoimmunity in a Mouse Model
Abstract Number: 2552

Alterations in the Colonic Microbiome Precede the Development of Murine Inflammatory Arthritis
Abstract Number: 2462

Altered Expression of IL-10 Family Cytokines in Chronic Recurrent Multifocal Osteomyelitis Result in Enhanced Inflammasome Activation
Abstract Number: 1132

Altered Histone 3 Dynamics at the Matrix Metalloproteinase 1 (MMP1) Transcription Start Site Contributes to MMP1 Suppression in Betaine Supplemented Synovial Fibroblasts in Rheumatoid Arthritis
Abstract Number: 283

Altered Serum Fatty Acid Profiles in Patients with Polymyositis or Dermatomyositis Compared to Healthy Individuals and in Relation to Immunosuppressive Treatment
Abstract Number: 13

Altered Soluble Mediators, Autoantibodies, and Lupus-Specific Connective Tissue Disease Questionnaire Scores Distinguish Blood Relatives with Incomplete Lupus from Unaffected Relatives and Relatives with Classified SLE
Abstract Number: 961

Altered Th Cell Plasticity Favors Th17 Cells in Rheumatoid Arthritis
Abstract Number: 2976

Ambrisentan Dose Migration over 3 Years in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (CTD-PAH)
Abstract Number: 1181

Ambulatory Rheumatology Curriculum: Effect of Fellow Teaching Multimodal Simulation Curriculum Enhancement
Abstract Number: 1378

AMP-Activated Protein Kinase As an Anti-Inflammatory Target for Methotrexate
Abstract Number: 2741

An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Abstract Number: 123

An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].